FINWIRES · TerminalLIVE
FINWIRES

UBSは、米国市場の好調な推移を受け、スターバックスの第2四半期の売上高と利益は上方修正されるとの見通しを示した。

-- UBS証券は火曜日のレポートで、スターバックス(SBUX)が間もなく発表する第2四半期決算は、加速する売上動向を支える施策の進展を示すと予想され、売上高、利益率、そして利益に上方修正の余地があると述べた。 同社は4月28日に第2四半期決算を発表する予定だ。 UBSは、北米の第2四半期既存店売上高が従来予想の4%から6%に上方修正され、市場コンセンサスの4%を上回ったとしている。また、客単価は1%、取引件数は5%の伸びを予測している。 同証券会社は、メニュー革新、ベーカリーの新ラインナップ、グリーンエプロンサービスの継続的な効果、業務改善といった戦略計画の成果により売上が改善していると述べ、北米の既存店売上高は第3四半期に5%、2026年度には4.7%増になると予想している。 さらに、同投資会社は、インフレ率の緩和、投資の繰り越し、コスト削減計画に支えられ、第2四半期の調整後営業利益率は8.6%になると予測しており、これは市場予想の8.3%を上回る。2026年度の営業利益率は10.6%になると予想している。 UBSは同社株を中立と評価し、目標株価を100ドルとしている。

Price: $97.35, Change: $-1.60, Percent Change: -1.62%

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703